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Subcutaneous Testosterone Is Effective and Safe as
Gender-Afﬁrming Hormone Therapy in Transmasculine
and Gender-Diverse Adolescents and Young Adults:
A Single Center’s 8-Year Experience
Sarah E. Laurenzano,1 Ron S. Newﬁeld,2 Euyhyun Lee,3 and Maja Marinkovic2,*
Abstract
Purpose: To describe our Center’s 8-year experience with subcutaneous testosterone (SC-T) as gender-afﬁrming
hormone therapy (GAHT) in transmasculine and gender-diverse (TM/GD) youth.
Methods: An Institutional Review Board (IRB)-approved retrospective study for 119 TM/GD subjects who started
SC-T at age 13–19 and received SC-T for > 6 months between 2012 and 2020.
Results: SC-T was typically started at 25–50 mg biweekly and dose was escalated at provider’s discretion. Over
96% of subjects were on 100–320 mg monthly (divided weekly or biweekly) at last follow-up. There was an overall increase in mean total and free testosterone (T) over the dose range ( p = 0.003), with mean total and free
T levels of 460 ng/dL and 92 pg/mL, respectively, at a monthly SC-T dose of 200 mg. For subjects on SC-T without
additional menstrual suppression, 54% had cessation of menses at 140 mg monthly and 97% at 200 mg monthly.
On average, menses stopped 4.7 (standard deviation 3.0) months after starting SC-T. There was a decrease in
high-density lipoprotein and increase in hematocrit from baseline to follow-up. Body mass index Z-scores did
not change signiﬁcantly with treatment. Mild acne was common; severe acne and signiﬁcant injection site
reactions were uncommon. Sustained hypertension, transaminitis, and dyslipidemia were infrequent.
Conclusions: SC-T is well tolerated and effective in reaching recommended T levels and stopping menses in TM/GD
youth. Occurrence of serious adverse effects is low and inability to tolerate injections is very uncommon. SC-T is a safe
and effective alternative to intramuscular testosterone in initiation and maintenance of GAHT in TM/GD youth.
Keywords: adolescent; subcutaneous; testosterone; transmasculine; young adult

Background
Testosterone (T) replacement therapy is utilized in
hypogonadal cismales and as gender-afﬁrming hormone therapy (GAHT) for transmasculine and genderdiverse (TM/GD) adults and youth.1,2 T replacement
can be given as intramuscular (IM) injection, transdermally (patch or gel), orally, or as an implant. In addition to higher treatment cost often associated with
transdermal formulations, patches may irritate skin
and are unavailable in small/gradually incrementing

doses, while T-gel carries the risk of inadvertent transfer to close contacts. Other T formulations considered
less accessible or desirable include oral (not readily
available for use in the United States) and implantable
subcutaneous pellets (dose cannot be quickly adjusted
as pellets are in place for several months and carry
risk of dermatitis, infection, or extrusion3). Therefore,
it is often preferred to use an injectable form of T as
GAHT. Subcutaneous testosterone (SC-T) injections
are approved for T enanthate administration for adults
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only using a costly self-injector device. Studies in adult
transgender patients have suggested that SC-T is well
tolerated with stable and therapeutic serum T levels.4,5
Studies in hypogonadal adult cisgender males also indicate that SC-T is safe and well tolerated with steady
pharmacokinetic proﬁle.6–8 Although one study using
injectable depot T undecanoate (formulation not used
in our Center) showed some preferred IM route over
SC,9 another study using T cypionate and enanthate
(the two formulations most commonly used in our
center) showed all participants who had utilized both
routes preferred SC administration.10
Thus, interest in SC-T for TM/GD youth has increased, but extensive pediatric data are lacking.
Olson et al.11 showed good efﬁcacy and tolerability of
SC-T with favorable adverse effect proﬁle in transgender youth and young adults (aged 13–24). The study
limitations were a relatively small cohort (36 subjects)
and short (6-month) follow-up. Since our clinic was
established in 2012, we have almost exclusively had patients administer T-SC as opposed to IM. Patients at
our center are started on biweekly (every 2 weeks) injections and at follow-up are offered to switch to weekly
SC-T. Although some choose to stay on biweekly injections, the majority prefer weekly dosing especially if
experiencing mood changes related to peak or nadir
of biweekly SC-T dosing. Our large patient population
has received SC-T over many years, which enables us to
further characterize the efﬁcacy, safety, and tolerability
of SC-T in TM/GD youth. In our center, SC-T is typically initiated around age 14 or older, after multidisciplinary assessment of readiness, in youth with gender
dysphoria who desire GAHT, and have no contraindications. We use a gradually increasing dose schedule in
keeping with published guidelines.1,2
Objectives
Our primary objective was to assess the effectiveness
and safety of SC-T in achieving recommended T levels
and cessation of menses in TM/GD youth. As the two
providers in our center differ in recommendations for
timing of blood draws for T levels (Provider A: midway
between injections; Provider B: just before the next injection is due/trough level), a secondary objective was
to describe differences in T levels at different time
points since the previous injection and when given
weekly or biweekly. In addition, we assessed the average SC-T dose and time since starting SC-T, at which
cessation of menses occurred, and the frequency of
adverse events.
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Methods
This retrospective, single-center study to evaluate SC-T
as GAHT in TM/GD youth was conducted at Rady
Children’s Hospital San Diego (RCHSD), California,
between August 2012 and February 2020. All 119
subjects were younger than the age of 21 years when
starting SC-T and received SC-T for a minimum of
6 months. Study subjects consented (assented when
applicable) into an Institutional Review Board (IRB)approved endocrine database. Subjects were assessed
by a mental health professional for readiness to start
SC-T and met diagnostic criteria for gender dysphoria
by WPATH Standards of Care version 7 guidelines.2
All subjects (and parents/guardians if < 18) signed informed consent for T start. Subjects were taught and
supervised by a nurse how to self-administer ﬁrst
SC-T injection (using an 18-gauge needle to draw
and a 25-gauge to inject).
Age at ﬁrst presentation to clinic and at SC-T start,
gender identity, race, and ethnicity were documented.
Baseline and follow-up body mass index (BMI; kg/m2)
and BMI Z-score (for subjects younger than the age
of 20 years, using CDC age 2–20 standards for cisgender
females12) were documented to assess for change over
treatment period. We collected baseline and ontreatment T levels during the follow-up period (deﬁned
as the date of T start to date of the most recent T level
check). We included four subjects with laboratory
follow-up < 6 months, but ofﬁce follow-up 6 months
or more. When multiple levels were checked on the
same SC-T dose, the ﬁnal value obtained on a given
dose was recorded. The majority (close to 90%) of T levels were measured using liquid chromatography with
dual mass spectrometry (LC-MS/MS) assay (most at
Quest Diagnostics, remainder at ARUP). A minority
of T levels were performed at LabCorp using electrochemiluminescence immunoassay (ECLIA).
Data on menstrual patterns included time to cessation of menses and SC-T dose at which this occurred.
The effect of SC-T on cessation of menses did not
include subjects treated with gonadotropin-releasing
hormone (GnRH) agonists or other forms of menstrual suppression (e.g., combined oral contraceptive
or progesterone-only pills) or who were premenarchal
before SC-T start.
We recorded baseline and follow-up values of ultrasensitive estradiol, AST, ALT, hematocrit, and lipids:
total cholesterol, high-density lipoprotein (LDL), highdensity lipoprotein (HDL), and triglycerides. Presence
of any injection-site reaction and circumstances were
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recorded. We documented subjects with systolic blood
pressure (SBP) or diastolic blood pressure (DBP) > 95th
percentile for age and height if < 18 years, or SBP
> 140, or DBP > 90 mm/Hg if > 18, for three consecutive visits. Presence of acne at baseline, progression
during SC-T therapy, and treatment of acne including
whether a referral was made to dermatology were
noted.
De-identiﬁed data from the eligible subjects were
entered into the Research Electronic Data Capture
(REDCap) database securely hosted at RCHSD, including date of birth as approved by the IRB. REDCap is a
secure, web-based software platform designed to support data capture for research studies.13,14 For statistical analysis, we used two-sample t-test and chi-square
test to compare continuous variables and categorical
variables, respectively, between groups. We used paired
t-test to analyze changes in various laboratory values
within each group. When there were more than two
groups, analysis of variance was used to compare differences between groups.
Results
Baseline characteristics
At presentation to our center, the majority of subjects had a transmale/male gender identity (Table 1);
others identiﬁed as nonbinary or had other genderdiverse identities. The majority of them were Caucasian
and approximately one-quarter identiﬁed as Latinx/
Hispanic. Mean baseline BMI Z-score was normal
at 0.55. Nineteen subjects (16%) were overweight
(BMI ‡ 85% and < 95%, Z-score 1.05–1.64) and 24 subjects (20.2%) were obese (BMI ‡ 95%, Z-score > 1.64);
3 subjects (2.5%) were underweight (BMI < 5%,
Z-score less than 1.64). Average age at presentation
to clinic was 16 years (range 10.1–19.8 years) and at
the time of SC-T start was 16.5 years (range 13–19.9
years); six subjects started SC-T younger than the age
of 14 years, per individualized approach. Nearly all
subjects were started on 50–100 mg SC-T monthly
divided into every 2 weeks (biweekly) doses; two subjects misunderstood instructions and started on 120–
140 mg SC-T monthly.
Median follow-up was 1.9 years and ranged from
6 months to 5.5 years.
Final T levels
SC-T dose was increased typically every 3–6 months
guided by serum T levels, patient’s preference, and
timing of follow-ups. The last available SC-T dose
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Table 1. Demographic and Baseline Characteristics Before
Starting Subcutaneous Testosterone
Total
Age at presentation in years (range)
Age at SC-T start in years (range)
Gender identity (%)
Transmale/male
Othera
Nonbinary

119
16 (10.1–19.8)
16.5 (13–19.9)
110 (92.5%)
6 (5%)
3 (2.5%)

Race (%)
Caucasian
Asian
Native American/Alaska Native
African American
Native Hawaiian/Paciﬁc Islander
Unknown/unavailable
Otherb

79
7
4
2
1
20
17

Ethnicity (%)
Non-Hispanic/Latinx
Hispanic/Latinx
Unknown

88 (73.9%)
29 (24.4%)
2 (1.7%)

BMI, kg/m2 average (SD)
BMI Z-score average (SD)
BMI Z-score category (%)
Obese
Overweight
Underweight
On menstrual suppression before start SC-T (%)
No
GnRHa
Other (progesterone only; combined oral
contraceptive)

(66.4%)
(5.9%)
(3.4%)
(1.7%)
(0.8%)
(16.8%)
(14.3%)

24.85 (7.26)
0.55 (1.22)
24 (20.2%)
19 (16%)
3 (2.5%)
99 (83.2%)
12 (10.1%)
8 (6.7%)

a
Other gender identities included gender queer (n = 1), gender queer
or ﬂuid (n = 1), gender ﬂuid (n = 1), agender (n = 1), on the gender spectrum (n = 1), no preferred gender identity, or pronoun expressed at
ﬁrst visit (n = 1). Age at presentation and age at T start expressed as
mean (range). BMI and BMI Z-score expressed as mean (SD).
b
Other self-reported races included: Mexican (n = 1), Peruvian (n = 1),
Puerto Rican (n = 1), and Hispanic not otherwise speciﬁed (n = 14).
BMI, body mass index; GnRHa, gonadotropin-releasing hormone agonist; SC-T, subcutaneous testosterone; SD, standard deviation; T, testosterone.

and corresponding total and free serum T levels were
recorded (Fig. 1a, b). As free T measurements by
ECLIA (LabCorp) were signiﬁcantly lower than those
measured by LC-MS/MS (Quest and ARUP), free T
levels performed at LabCorp (representing a minority
of subjects) were omitted from the free T analysis.
The majority of subjects (n = 94, 79%) were on 100–
200 mg of SC-T monthly; an additional 21 subjects
(18%) were on 240–320 mg of SC-T monthly. Across
all ﬁnal SC-T doses, 70% (n = 83) were on weekly injections. In those that reached a monthly SC-T dose of
200 mg or more, 83% were on weekly injections. For
those at 100 mg or more of SC-T monthly, mean
total T level ranged from 274 to 534 ng/dL and mean
free T levels 43–129 pg/mL. The most common ﬁnal
SC-T dose, taken by 49 (41%) subjects, was 200 mg
monthly. Mean total and free T levels at 200 mg
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FIG. 1. (a, b) Mean total (a) and free testosterone level (b) at ﬁnal testosterone doses. Bars represent standard
error of the mean. SC-T, subcutaneous testosterone; T, testosterone.

monthly were 460 ng/dL and 92 pg/mL, respectively,
and there was no difference in total and free T levels
between the 38 on weekly dosing (458.5 ng/dL and
91.9 pg/mL, respectively) and the 11 on biweekly dosing
(465.9 ng/dL and 91.8 pg/mL, respectively) at this dose.

Cessation of menses
Data on SC-T dose at which menses stopped were
available for 78 subjects. The majority (76/78, 97.4%)
of these subjects achieved cessation of menses on
total monthly SC-T dose of 200 mg (Fig. 2). Over half
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Cumulative percentage of subjects with cessation of menses by ﬁnal SC-T dose.

(53.9%) had cessation of menses when monthly SC-T
dose of 140 mg was reached.
Data on time from SC-T start to cessation of menses
were available for 81 subjects. On average, menses stopped 4.7 (standard deviation [SD] 3.0) months after starting SC-T: 5.4 (SD 2.9) months if starting monthly dose
was 50 mg and 3.9 (SD 3.0) months if it was 100 mg
( p = 0.025). There were seven subjects (5.9%) in whom
it took > 400 days to stop menses; three of these had
interruptions in adherence/supply or follow-up.
Differences in timing of the blood draws
We compared total and free T levels at various SC-T
doses between two groups, those followed by Provider
A (who recommends mid-injection blood draws) and
those followed by Provider B (who recommends trough
blood draws) (Fig. 3a, b). As the majority of subjects
(n = 83, 70%) were on weekly dosing at ﬁnal SC-T
dose, we omitted those on biweekly dosing from the
analysis. We did not observe statistically signiﬁcant differences in mean total or free T levels between providers A and B.
Changes in BMI, BMI Z-score, and assessment
of correlation with ﬁnal SC-T dose
Mean follow-up BMI was 25.71 kg/m2, an increase of
0.86 kg/m2 from mean baseline BMI ( p < 0.001). BMI

Z-scores at the start and end of study period were available for 95 subjects, as 24 subjects had turned 20 during
study period. For those 95, mean BMI Z-score before
SC-T start and at last follow-up was 0.56 (1 SD =
1.26) and 0.50 (1 SD = 1.26), respectively ( p = 0.334).
There was no statistically signiﬁcant correlation between a higher ﬁnal SC-T dose and ﬁnal BMI Z-score.
Laboratory parameters for subjects on different
SC-T doses
To assess effect of SC-T from baseline to follow-up on
laboratory parameters, as well as the effect of increasing
SC-T dose on changes in parameters, the cohort was
subdivided into three dosing groups for further analysis: those on relatively low ﬁnal SC-T dose ( < 160 mg
monthly), those on an average dose of 160–240 mg
monthly (the majority of subjects), and those on a relatively high dose of > 240 mg monthly (Table 2). There
were statistically signiﬁcant increases in total and free T
and decrease in estradiol from baseline to follow-up,
as expected. The effect of increasing SC-T dose on
ﬁnal total T ( p = 0.003) and free T ( p < 0.001) was signiﬁcant, and similarly, the changes in total and free T
were also signiﬁcant. The change in total and free T
at each dosing group was signiﬁcant ( p < 0.001). There
was a statistically and clinically signiﬁcant decrease in
HDL of 6.42 mg/dL from baseline to follow-up for the

FIG. 3. (a, b) Testosterone levels based on timing of blood draw. (a) Bar plot of total T level for patients of
Provider A and Provider B, on weekly dosing. (b) Bar plot of free T level for patients of Provider A and Provider B,
on weekly dosing. Provider A, mid-dose level; Provider B, trough level.
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Table 2. Laboratory Values at Baseline and on Final Subcutaneous Testosterone Dose, at and Across Three Dose Ranges
Parameter, mean (SD), [p value]
for each D at each SC-T dose
Baseline total T, ng/dL
Final total T, ng/dL
D total T, ng/dL
Baseline free T, pg/mL
Final free T, pg/mL
D free T, pg/mL
Baseline estradiol, pg/mL
Final estradiol, pg/mL
D Estradiol, pg/mL
Baseline TC, mg/dL
Final TC, mg/dL
D TC, mg/dL
Baseline HDL-C, mg/dL
Final HDL-C, mg/dL
D HDL-C, mg/dL
Baseline LDL-C, mg/dL
Final LDL-C, mg/dL
D LDL-C, mg/dL
Baseline TG, mg/dL
Final TG, mg/dL
D TG, mg/dL
Baseline hematocrit, %
Final hematocrit, %
D Hematocrit, %
Baseline AST, U/L
Final AST, U/L
D AST, U/L
Baseline ALT, U/L
Final ALT, U/L
D ALT, U/L

SC-T/month,
< 160 mg (n = 28)

SC-T/month,
160–240 mg (n = 81)

SC-T/month,
> 240 mg (n = 10)

Overall
(n = 119)

Trend across dose
range: p-value

29.2 (14.8)
328.8 (185.5)
287.1 [a]
3.8 (3.7)
53.9 (30.9)
47.2 [a]
81.3 (70.4)
52.9 (31.2)
67.6 [0.036]
161.0 (28.8)
155.6 (28.0)
5.4 [0.362]
50.4 (15.0)
45.6 (12.6)
3.7 [0.08]
90.4 (22.6)
93.0 (26.2)
0.4 [0.928]
96.9 (38.8)
96.8 (42.5)
1.3 [0.926]
39.4 (2.7)
43.1 (3.1)
3.7 [a]
24.4 (10.3)
20.8 (7.3)
4.3 [0.024]
20.1 (11.2)
18.4 (9.6)
2.0 [0.353]

31.6 (13.6)
456.8 (190.6)
424.6 [a]
3.6 (2.4)
91.9 (45.3)
89.3 [a]
79.6 (71.1)
48.4 (50.3)
30.7 [0.001]
156.2 (29.8)
151.8 (32.3)
4.5 [0.182]
50.2 (13.2)
43.5 (9.3)
6.7 [a]
90.4 (25.4)
91.1 (24.5)
0.4 [0.899]
87.6 (34.0)
97.5 (59.3)
9.0 [0.276]
39.1 (2.5)
44.1 (3.3)
5.1 [a]
21.3 (7.3)
23.6 (9.5)
2.4 [0.060]
21.0 (9.7)
21.3 (13.8)
0.4 [0.824]

37.8 (15.8)
522.6 (162.6)
484.7 [a]
4.5 (1.8)
124.6 (47.9)
120.1 [a]
68.6 (52.66)
47.3 (28.6)
27.0 [0.293]
165.2 (33.9)
170.7 (25.5)
5.5 [0.452]
47.6 (8.5)
39.5 (7.5)
8.1 [0.016]
101.3 (28.8)
104.3 (22.2)
2.9 [0.602]
87.5 (38.5)
128.6 (86.4)
41.1 [0.092]
40.1 (2.7)
46.5 (3.3)
6.4 [a]
19.0 (4.6)
23.4 (7.0)
4.4 [0.078]
20.3 (10.5)
30.0 (9.7)
9.7 [0.041]

31.6 (14.1)
432.2 (195.4)
399.3 [a]
3.7 (2.6)
86.2 (46.5)
84.3 [a]
78.9 (69.0)
49.1 (45.7)
34.7 [a]
158.0 (29.8)
154.6 (31.1)
3.5 [0.194]
50.0 (13.2)
43.4 (9.8)
6.4 [a]
91.4 (25.1)
92.9 (24.7)
0.2 [0.922]
89.6 (35.4)
100.8 (60.5)
11.4 [0.100]
39.2 (2.6)
44.1 (3.3)
4.9 [a]
21.8 (8.0)
23.0 (8.8)
1.1 [0.290]
20.8 (10.0)
21.4 (12.9)
0.7 [0.600]

0.269
0.003
0.003
0.619
a
a

0.894
0.938
0.372
0.575
0.202
0.497
0.833
0.301
0.488
0.427
0.296
0.883
0.541
0.309
0.237
0.48
0.024
0.054
0.115
0.349
0.010
0.908
0.050
0.054

D is the change from baseline to ﬁnal testosterone dose. Values in parentheses for each laboratory value is SD, and in brackets for the D it is the
p-value indicating if that change is signiﬁcant.
Statistical signiﬁcance: ap < 0.001.
HDL-C, high-density lipoprotein cholesterol; LDL-C, high-density lipoprotein cholesterol; TC, total cholesterol; TG, triglycerides.

whole cohort ( p < 0.001); however, the effect of increasing SC-T dose on change in HDL was not statistically
signiﬁcant. There was a signiﬁcant increase in hematocrit from baseline to follow-up at each dosing group
( p < 0.001), and there was a signiﬁcant increase in hematocrit as SC-T dose increased ( p = 0.024) and a tendency for the change in hematocrit from baseline to
increase across the three groups ( p = 0.054). However,
ﬁnal mean hematocrit remained in the normal range
for males. There was a signiﬁcant effect of increasing
SC-T dose on change in AST ( p = 0.010) since there
was a drop at lower doses and increase on higher SC-T
doses. The absolute increase in mean AST from baseline
to follow-up of 1.11 U/L for the whole cohort was not
clinically signiﬁcant. The mean ﬁnal ALT value compared across the dose range was borderline statistically
signiﬁcant ( p = 0.05), but not clinically signiﬁcant.
Absolute values of and changes from baseline to
follow-up in other laboratory parameters and the effect
of increasing dose on these values and changes were
not statistically signiﬁcant.

Clinical adverse events and changes
in SC-T therapy
Local reaction. Mild injection site reactions during
SC-T therapy were documented in 14 subjects (11.8%).
The spectrum of reactions included skin lumps, pruritus,
swelling, erythema, focal hair growth at the site (n = 2, as
previously reported15), decreased sensation (n = 1, limited to a single site), and skin infection. Two cases of
skin infection during SC-T therapy occurred: one subject
had cellulitis after not properly cleaning skin before injection (without recurrence), and one subject had two
abscesses. Neither subject with skin infection changed
their SC-T therapy. In total, only 4/14 subjects with
documented injection site reactions changed therapy
in some way. Three subjects changed from SC-T cypionate to SC-T enanthate with resolution of symptoms,
and one subject switched to T-gel because of pain and
swelling with injections.
Hypertension. No subjects developed hypertension
that was felt to be related to SC-T therapy or required
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antihypertensive treatment. Six subjects had either SBP
or DBP > 95th percentile for age on three consecutive
visits, which did not appear to be true hypertension;
four of these subsequently had a blood pressure (BP)
below this threshold. One subject had consistently elevated SBP and pulse both at T start and during therapy,
thought to be related to anxiety, but did not have consistently elevated DBP and no intervention was taken
to lower BP. Another subject had consistently elevated
BP in our center, however, on outside assessment had
normal BP and electrocardiogram.
Acne. Acne at baseline was noted for 61/106 (57.5%)
subjects who had acne documentation; the majority of
acne was mild to moderate. Progression of acne was
documented for 77/119 subjects (64.7%); advanced
acne management (oral treatment and/or referral to
dermatology) was documented in 23/119 (19.3%).
None stopped SC-T.
Descriptive review of adverse effects on laboratory
parameters. No subjects developed transaminitis related to SC-T therapy.
One subject developed worsening of dyslipidemia
while on SC-T. His baseline LDL was 120 mg/dL but
increased to > 160 mg/dL starting 6 months after
SC-T start. Hyperlipidemia was treated with low-dose
statin with good response. Of note, his BMI increased
from normal to obese over follow-up.
No subjects developed hematocrit > 55%. Six subjects (5%) had hematocrit > 50% at some point. Highest recorded hematocrit in the cohort was 53.9% in a
subject receiving SC-T 100 mg biweekly; hematocrit
decreased subsequently without dose change. SC-T
dose was transiently decreased due to high-normal T
level (822 ng/dL) and mildly increased hematocrit
(51.4%, hemoglobin 17.4 g/dL) for one subject on
SC-T for 15 months. Dose was readjusted to 60 mg
weekly at follow-up (hematocrit = 51%, hemoglobin =
16.9 g/dL, and corresponding T = 466 ng/dL). Another
subject had slight SC-T dose decrease due to borderline
high hematocrit = 49.8% in the setting of upper-normal
free T = 131.7 (18–111 pg/mL).
Variance from prescribed dosing. Per chart review, at
some point in their therapy, 31.1% of the cohort
slightly deviated from the dose or schedule recommended by the provider: subjects giving minimally
different doses than prescribed, or injections being
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occasionally delayed or missed due to interruption in
supply, follow-up, or adherence.
Subjects who discontinued SC-T. In addition to the
one subject who stopped SC-T and switched to T-gel
because of pain/swelling with injections, three additional subjects without local/cutaneous reaction to
SC-T chose to change treatment. One subject switched
from SC-T to T-patch 8 months after SC-T start due to
needle phobia; one subject switched from SC-T to T-gel
after 1 year on SC-T due to pain and difﬁculty injecting
himself; and one subject switched from adult dose of
SC-T to T-gel after 3 years of SC-T therapy simply
due to preference. Three subjects stopped SC-T altogether due to desire to end masculinizing therapy.
Two stopped because they were satisﬁed with effects of
SC-T achieved and one stopped within 6 months of
starting after reassessing their gender identity. This
subject started GAHT at age 16.5 years with SC-T
dose of 25 mg biweekly, subsequently increased to
25 mg weekly. The subject decided to stop SC-T
6 months after starting due to concerns about body
changes and potential impact on fertility. Unfortunately, this subject was lost to follow-up and no longterm outcome is available.
Conclusions/Discussion
This study, to date the largest pediatric study of SC-T,
adds to the currently limited literature supporting the
efﬁcacy and safety of SC-T as an alternative to IM testosterone injections for GAHT in TM/GD youth. Dose
of SC-T required to achieve mean total T levels in
the goal range (400–700 ng/dL when measured midinjection1) and achieve cessation of menses for the majority of our study subjects was 140–200 mg monthly,
which is similar to or lower than those suggested by
guidelines1 as adult doses for IM or SC-T (100–
200 mg every other week). Of note, a small subset of
subjects did not achieve the ultimately intended dose
due to limited follow-up and some subjects requested
lower-than-typical doses.
We observed an overall increase in mean total and
free T levels as SC-T dose increased, with slight deviations from this pattern noted in those individuals on
a ﬁnal T dose of 120 mg monthly and on 320 mg
monthly (these subgroups were small, n = 7 and n = 4,
which may have accounted for deviation from overall
trend). There was a wide spread in the ranges of ﬁnal
total and free T levels obtained in different subjects
on the same SC-T dose, and signiﬁcant overlap
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between the ranges of T levels obtained on different
SC-T doses. This ﬁnding likely speaks to the signiﬁcant
interindividual variability in SC-T dose requirements
and highlights the importance of monitoring T levels.
An additional factor to consider is the challenge of imperfect adherence to SC-T therapy and recommendations for timing of serum T level checks. Indeed,
chart review supported that nearly one-third of subjects
took SC-T slightly differently than it was prescribed at
some point during treatment course, although usually
for short periods. We did not ﬁnd the expected correlation of higher T levels when purportedly assessed as
mid-injection compared to as a trough. This lack of
an expected ﬁnding is most likely due to improper timing of the blood draw (i.e., deviating from providers’
instructions).
Cessation of menses occurred on average 4.7 months
after starting SC-T, and it took longer in those on
50 mg versus 100 mg as a monthly starting dose. Therefore, when faster cessation of menses is desired (and no
concerns about acne or height), we suggest to start
SC-T at 100 mg/month. While adherence or lack of
follow-up can be contributing factors, some patients
may need a GnRH agonist or progestin to achieve
amenorrhea. If ongoing menses is a cause of signiﬁcant
dysphoria for an individual, an additional form of
menstrual suppression should be offered right away.
We found that adverse effects of SC-T were uncommon. Progression of acne was common, as expected
with T therapy, but severe acne was uncommon.
Hypertension necessitating antihypertensive treatment
was not observed. In our cohort, the absolute BMI
increase from baseline to follow-up was due to the increase of BMI with increasing age, but there was no difference when comparing BMI Z-scores adjusted for
age. Therefore, pediatric studies should only compare
BMI Z-scores. Being on a higher SC-T dose did not
affect the BMI Z-score.
Similar to a recent study of transgender male
youth,16 we found an increase in hematocrit that
was statistically signiﬁcant; however, mean ﬁnal hematocrit was still in the normal range for males. While six
subjects had hematocrit > 50% at some point during
SC-T therapy, only two required small dose adjustments. Some had transient hematocrit increase when
fasting, due to hemoconcentration, which was corrected with nonfasting samples. Importantly, while
some consider a hematocrit of 50% the upper limit
of normal for adult males,17 hematocrit up to 54%
is considered high-normal by others.18 Cessation of
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SC-T therapy or other treatments for polycythemia
were not required for any subjects.
Although increases in AST and ALT from baseline to
ﬁnal follow-up were statistically signiﬁcant and borderline signiﬁcant, respectively, those were not clinically
signiﬁcant and follow-up values for both parameters
remained normal.
Dyslipidemia after SC-T start requiring additional
treatment occurred in only one subject. He started a
statin because of increased LDL cholesterol, which is
not typically associated with T therapy, but likely due
to obesity that developed over the follow-up period.
HDL lowering, an expected effect of testosterone therapy, and lower estradiol levels, has been substantiated
in recent pediatric studies.16,19 We also observed a statistically and clinically signiﬁcant decrease in HDL
from baseline to follow-up in the overall cohort; this
decrease in HDL did not seem to worsen on higher
SC-T doses. Counseling about the importance of increased physical activity, while being sensitive to barriers to exercise in this population such as exacerbation
of dysphoria or restricted exercise capacity due to chest
binding, is crucial in helping raise HDL and can aid in
improving mental health and weight management.
Injection site reactions occurred rarely; only 3/119
(2.5%) subjects were unable to tolerate SC-T.
Particular strengths of our study include the large
size and diversity of this cohort and the long experience
with using SC-T in a real-world setting. This is the
largest study of SC-T use in the pediatric population
published to date, with safety laboratories repeated
over time and with a sufﬁcient follow-up duration to
adequately assess for adverse effects.
The primary limitations of the study are its retrospective nature and single-center cohort. Detailed information on exact timing of blood draws was not always
possible to ascertain retrospectively, so separation of
the cohort into mid-injection or trough T levels based
on treating providers may not have been accurate in
all cases. However, we feel that the size of the cohort is
large enough for us to reasonably conclude that timing
of the blood tests did not make a signiﬁcant impact on
serum T levels. Finally, imperfect adherence to therapy
as prescribed was noted, but usually for brief periods.
Adherence is a common challenge in adolescents in general, and we feel that inclusion of all subjects with reasonable adherence to treatment and follow-up was
important, as it reﬂects real-world conditions.
As SC-T is not an FDA-approved route for
T-cypionate, this publication is a valuable addition to
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the medical literature relevant not only to TM/GD
individuals but also to cisgender hypogonadal adolescents and young adults. We conclude that SC-T is
effective in TM/GD youth in achieving adult male
serum T levels and cessation of menses. No subjects
had to stop SC-T because of serious adverse effects
on BP, acne, transaminases, lipid proﬁle, or hematocrit.
Overall, tolerance of SC-T was very good. We recommend, based on our extensive experience, that providers consider SC-T as an excellent alternative to IM T
for initiation and maintenance of GAHT in TM/GD
youth.
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